Aardvark Therapeutics, Inc. income statement AARD

In fiscal 2025, which ended Dec 31, 2025, Aardvark Therapeutics, Inc. reported revenue of $0. It recorded a net loss of $57.6 million. Diluted earnings per share were -$2.93. Over the twelve months ended Jun 30, 2026, revenue was $0 and the net loss was $69.9 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Revenue
0
0
Research and development
55
49
Selling, general and administrative
19
14
Operating income
-74
-63
Income tax
—
0
Net income
-70
-58
Basic EPS
-3.21
-2.93
Diluted EPS
-3.21
-2.93
Weighted average shares, basic
22
20
Weighted average shares, diluted
22
20
Other measures
Depreciation and amortization
0
0
EBITDA
-74
-63
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AARD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
1774857

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.